1. Home
  2. LARK vs NGEN Comparison

LARK vs NGEN Comparison

Compare LARK & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Landmark Bancorp Inc.

LARK

Landmark Bancorp Inc.

HOLD

Current Price

$30.75

Market Cap

171.0M

Sector

Finance

ML Signal

HOLD

NGEN

NervGen Pharma Corp. Common stock

N/A

Current Price

$1.86

Market Cap

197.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
LARK
NGEN
Founded
1885
2017
Country
United States
Canada
Employees
N/A
9
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
171.0M
197.5M
IPO Year
2001
N/A

Fundamental Metrics

Financial Performance
Metric
LARK
NGEN
Price
$30.75
$1.86
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$18.00
AVG Volume (30 Days)
12.2K
893.1K
Earning Date
04-29-2026
04-02-2026
Dividend Yield
3.07%
N/A
EPS Growth
35.84
N/A
EPS
0.83
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$36.61
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.57
$1.70
52 Week High
$30.80
$5.93

Technical Indicators

Market Signals
Indicator
LARK
NGEN
Relative Strength Index (RSI) 77.35 34.21
Support Level $25.46 $1.70
Resistance Level N/A $4.44
Average True Range (ATR) 0.72 0.17
MACD 0.18 0.06
Stochastic Oscillator 100.00 25.19

Price Performance

Historical Comparison
LARK
NGEN

About LARK Landmark Bancorp Inc.

Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and Southwest Kansas.

About NGEN NervGen Pharma Corp. Common stock

NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.

Share on Social Networks: